Lantheus Holdings, Inc. (LNTH)

Market Cap	5.70B
Revenue (ttm)	1.54B
Net Income (ttm)	254.32M
Shares Out	69.19M
EPS (ttm)	3.53
PE Ratio	23.34
Forward PE	12.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,838,380
Open	79.19
Previous Close	79.19
Day's Range	79.01 - 83.74
52-Week Range	73.11 - 126.89
Beta	0.12
Analysts	Strong Buy
Price Target	131.20 (+59.2%)
Earnings Date	Jul 30, 2025

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 808
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH
• Website: https://www.lantheus.com

Financial Performance

In 2024, Lantheus Holdings's revenue was $1.53 billion, an increase of 18.32% compared to the previous year's $1.30 billion. Earnings were $312.44 million, a decrease of -4.35%.

Analyst Summary

According to 5 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price target is $131.2, which is an increase of 59.20% from the latest price.

Price Target

$131.2

(59.20% upside)

Analyst Consensus: Strong Buy